Core Research Interest: Stroke and Cognitive Decline; Molecular Biology and Neuropathology of Stroke and Associated Cognitive Decline
Honors & Awards
FENS Neuroscience Grant award and FENS Voucher Programme Award, Federation of European Neuroscience Societies (FENS) & British Neuroscience Association (BNA) (11-15 July, 2020)
Best Non-Clinical Poster Presentation Award, Malaysian Virtual Stroke Conference, 2020 (14-16 August, 2020)
Senior Research Fellowship (SRF) Direct-SRF (Medical Science), CSIR- Govt. of India, New Delhi (1st April 2019 to 31st October, 2021)
Best Research Scholar of the Year Award, Nirma University (1st October, 2020)
IBRO-YITP award (US$ 1000), IBRO World Congress of Neuroscience and YITP-IBRO Training at KBRI (21-25 September, 2019)
International Travel Grant award of 500 US $, IC-KDA (International Conference on Korean Dementia Association) (31st May-1st June, 2019)
International Travel Grant Award of US$ 500, Asian Oceanian Association of Neurology & South Korean Association of Neurology (8-11 November, 2018)
Educational Support Grant of worth (350 US $), 7th Asian-Oceanian Congress on Clinical Neurophysiology (9-12 April, 2020)
MS, National Forensic Sciences University, Neuropharmacology (2015)
PhD, Nirma University, Neuropharmacology, Neurology (2021)
Bingwei Lu, Postdoctoral Faculty Sponsor
Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination.
Brain, behavior, & immunity - health
2022; 22: 100463
Vaccination is an essential public health strategy to control the 2019 Coronavirus (COVID-19) pandemic. While the benefits of the COVID-19 vaccines far outweigh the risks, side effects continue to be reported in the literature. We report a 65-year-old man who developed cognitive deficits and memory impairments following his first dose of Oxford AstraZeneca vaccine (Covishield). The onset of acute cognitive deficits and memory impairments could be another complication to COVID-19 vaccination that physicians and neurologists need to be warned to. Monitoring the safety of COVID-19 vaccines and describing side effects associated with them is essential to improve safety profiles and enhance public trust.
View details for DOI 10.1016/j.bbih.2022.100463
View details for PubMedID 35496775
Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities.
2022; 14 (2): 391-405
Stroke is a fatal morbidity that needs emergency medical admission and immediate medical attention. COVID-19 ischemic brain damage is closely associated with common neurological symptoms, which are extremely difficult to treat medically, and risk factors. We performed literature research about COVID-19 and ischemia in PubMed, MEDLINE, and Scopus for this current narrative review. We discovered parallel manifestations of SARS-CoV-19 infection and brain ischemia risk factors. In published papers, we discovered a similar but complex pathophysiology of SARS-CoV-2 infection and stroke pathology. A patient with other systemic co-morbidities, such as diabetes, hypertension, or any respiratory disease, has a fatal combination in intensive care management when infected with SARS-CoV-19. Furthermore, due to their shared risk factors, COVID-19 and stroke are a lethal combination for medical management to treat. In this review, we discuss shared pathophysiology, adjuvant risk factors, challenges, and advancements in stroke-associated COVID-19 therapeutics.
View details for DOI 10.3390/neurolint14020032
View details for PubMedID 35645351
Modulating the Ubiquitin-Proteasome System: A Therapeutic Strategy for Autoimmune Diseases.
2022; 11 (7)
Multiple sclerosis (MS) is an autoimmune, neurodegenerative disease associated with the central nervous system (CNS). Autoimmunity is caused by an abnormal immune response to self-antigens, which results in chronic inflammation and tissue death. Ubiquitination is a post-translational modification in which ubiquitin molecules are attached to proteins by ubiquitinating enzymes, and then the modified proteins are degraded by the proteasome system. In addition to regulating proteasomal degradation of proteins, ubiquitination also regulates other cellular functions that are independent of proteasomal degradation. It plays a vital role in intracellular protein turnover and immune signaling and responses. The ubiquitin-proteasome system (UPS) is primarily responsible for the nonlysosomal proteolysis of intracellular proteins. The 26S proteasome is a multicatalytic adenosine-triphosphate-dependent protease that recognizes ubiquitin covalently attached to particular proteins and targets them for degradation. Damaged, oxidized, or misfolded proteins, as well as regulatory proteins that govern many essential cellular functions, are removed by this degradation pathway. When this system is affected, cellular homeostasis is altered, resulting in the induction of a range of diseases. This review discusses the biochemistry and molecular biology of the UPS, including its role in the development of MS and proteinopathies. Potential therapies and targets involving the UPS are also addressed.
View details for DOI 10.3390/cells11071093
View details for PubMedID 35406655
Extra-Neural Metastases From Primary Intracranial Ependymomas: A Systematic Review.
Frontiers in oncology
2022; 12: 831016
Background: Primary intracranial ependymomas (IE) are rare brain tumors rarely metastasizing outside the central nervous system. We systematically reviewed the literature on extra-neural metastases from primary IEs.Methods: PubMed, Scopus, Web-of-Science, and Cochrane were searched following the PRISMA guidelines to include studies of extra-neural metastases from primary IEs. Clinical features, management strategies, and survival were analyzed.Results: We collected 48 patients from 43 studies. Median age was 13 years (range, 2-65). Primary IEs were frequently located in the parietal (22.9%) and frontal (16.7%) lobes, and mostly treated with resection (95.8%) and/or radiotherapy (62.5%). Most IEs were of grade-III (79.1%), and few of grade-I (6.3%) or grade-II (14.6%). 45 patients experienced intracranial recurrences, mostly treated with resection (86.7%), radiotherapy (60%), and/or chemotherapy (24.4%). Median time-interval from primary IEs was 28 months (range, 0-140). Most extra-neural metastases were diagnosed at imaging (37.5%) or autopsy (35.4%). Extra-neural metastases were multifocal in 38 patients (79.1%), mostly involving cervical or hilar lymph-nodes (66.7%), lung/pleura (47.9%), and/or scalp (29.1%). Surgical resection (31.3%), chemotherapy (31.3%) and locoregional radiotherapy (18.8%) were the most common treatments for extra-neural metastases, but 28 (58.3%) patients were not treated. At last follow-up, 37 patients died with median overall-survivals from primary IEs of 36 months (range, 1-239), and from extra-neural metastases of 3 months (range, 0.1-36). Overall-survival was significantly longer in patients with grade-I and II IEs (P=0.040).Conclusion: Extra-neural metastases from primary IEs are rare, but mostly occur at later disease stages. Multidisciplinary management strategies should be intended mostly for palliation.
View details for DOI 10.3389/fonc.2022.831016
View details for PubMedID 35574408
- Delayed Bilateral, Post-Traumatic Extra-Subdural Hematomas in a Patient with Meningioma ONCOLOGIE 2022; 24 (2): 341-348